Heading into 2025, the chief item on argenx’s agenda is the FDA’s April 10 target action date to decide on the approval of a ...

Shares of Chimerix hit a new 52-week high Tuesday after the biopharmaceutical company said the Food and Drug Administration granted a priority review for its proposed dordaviprone treatment for a ...